Coronavirus disease (COVID-19) is an infectious disease caused by the coronavirus SARS-CoV-2. Here we have collected APR news related to the COVID-19 pandemic, vaccination efforts and emerging treatments.
Thursday, February 24, 2022
Novavax, Inc. announced the first doses of Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) have begun shipping to European Union (EU) member states. Nuvaxovid, also known as NVX-CoV2373, is the ...
read more
Thursday, February 24, 2022
Moderna, Inc. and Thermo Fisher Scientific Inc. announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing in the U.S. of Spikevax®, Moderna’s COVID-19 vaccine...
read more
Friday, February 18, 2022
Health Canada authorized Novavax's Nuvaxovid COVID-19 vaccine for the prevention of COVID-19 in adults 18 years of age and older. This is the fifth COVID-19 vaccine authorized in Canada. After a ...
read more
Thursday, February 17, 2022
Alvea will begin to develop, test, and deliver DNA vaccines at scale to low and middle-income countries with limited access to existing vaccine options.
read more
Wednesday, February 16, 2022
BioNTech SE has taken a next step to improve vaccine supply in Africa. The company has introduced its approach to establishing scalable vaccine production by developing and delivering turnkey mRNA ...
read more
Tuesday, February 15, 2022
Novavax, Inc. announced its submission to Swissmedic, the Swiss Agency for Therapeutic Products, for conditional marketing authorization (CMA) of NVX-CoV2373, its recombinant nanoparticle protein-...
read more
Monday, February 14, 2022
Eli Lilly and Company announced an agreement with the U.S. government to supply up to 600,000 doses of investigational drug bebtelovimab for at least $720 million.
read more
Monday, February 14, 2022
The U.S. Food and Drug Administration has been notified by Pfizer that new data have recently emerged regarding its emergency use authorization request for the use of the Pfizer-BioNTech COVID-19 ...
read more
Tuesday, February 08, 2022
Merck and Ridgeback Biotherapeutics announced that a total of approximately 3.1 million courses of molnupiravir, an investigational oral antiviral COVID-19 medicine, have been provided to the U.S. ...
read more
Tuesday, February 08, 2022
New research in the February 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms that mRNA vaccine for COVID-19 are just as safe for people with cancer as they are for ...
read more
Tuesday, February 08, 2022
Seqirus, a business of CSL Limited, announced an investment in a new Research and Development (R&D) facility located in Waltham, Mass. The new facility will support the company's growing R&D portfolio...
read more
Wednesday, February 02, 2022
The U.S. Food and Drug Administration approved a second COVID-19 vaccine. The vaccine has been known as the Moderna COVID-19 Vaccine; the approved vaccine will be marketed as Spikevax for the ...
read more
Wednesday, February 02, 2022
Novavax, Inc. and Israel's Ministry of Health announced an agreement for the purchase of NVX-CoV2373, the company's recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ ...
read more
Wednesday, February 02, 2022
Pfizer Inc. and BioNTech SE announced that following a request from the U.S. Food and Drug Administration (FDA) the companies have initiated a rolling submission seeking to amend the Emergency Use ...
read more
Merck and Ridgeback Biotherapeutics announced data from six preclinical studies demonstrating that molnupiravir, an investigational oral antiviral COVID-19 medicine, was active against the SARS-CoV-2 ...
read more